SPECIFICATION
Looking at the historical axis of global biopharmaceutical industry development, many changes are happening in 2025. We are in an environment full of uncertainty, and geopolitical frictions are still threatening the globalization trend of the biopharmaceutical industry, but the fundamentals of the biopharmaceutical industry may change by 2025. This article combines a review published in Nature to outline the five major changes that are happening in the pharmaceutical industry in 2025.
Tumor therapy: The rise of dual antibodies and innovative dosage forms, tumor therapy is still at the forefront of innovation, and is expected to see significant breakthroughs in 2025. Personalized cancer vaccines may become a reality, and there have been fruitful achievements in the field of bispecific antibodies. The improvement and innovation of drug formulations are also worthy of attention.
Weight loss drugs: In the past few years, GLP-1 drugs such as Novo Nordisk Simeglutide (Wegovy) and Mounjaro/Zepbound have driven rapid growth in the weight loss market. By 2024, the global weight loss prescription drug market is expected to exceed $30 billion. With the launch of oral semaglutide, the market may continue to grow.
The M&A market is full of potential: both buyers and sellers have urgent demands. Compared with the post pandemic M&A boom in 2023, M&A activities have cooled down since 2024. However, the M&A market in 2025 is still full of potential.
AI pharmaceutical applications and regulatory framework transformation: In order to ensure the safety and ethics of AI applications, as well as the correctness of their use, governments around the world are working to build a more comprehensive legal framework.
Patient led and self funded payment tendency: Nowadays, patients have access to many information channels and no longer rely solely on doctor's advice when taking medication. They hope to be able to make their own decisions on medication. For pharmaceutical companies that want to recoup their drug development costs, patients' autonomy and willingness to pay out of pocket can sometimes mean higher sales and market caps.
